ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

Roivant (ROIV) Q2 2026 Earnings: Revenue $35.1M, LISRAYA $31.0M

Автор: TalkTickers: AI Podcast Discussing Earnings Calls

Загружено: 2026-11-17

Просмотров: 1

Описание: Roivant Sciences (ROIV) reported fiscal second quarter 2026 results, for the quarter ended September 30, 2026, on November 9, 2026, its first quarter with LISRAYA on the market. LISRAYA (brepocitinib), approved by the FDA in August as the first oral treatment for adults with dermatomyositis, brought in $31.0 million of net product revenue in roughly five weeks on the market, lifting total revenue to $35.1 million from $1.6 million a year earlier, far above Wall Street estimates of roughly $2.6 million to $4 million. The GAAP net loss was $0.27 per share against estimates in the range of a $0.45 to $0.52 loss, the loss from continuing operations narrowed to $153.0 million from $166.0 million, and Roivant ended the quarter with about $4.2 billion in cash and marketable securities. The stock closed up 4.6% at $40.67 on the day of the call, while the biotech ETF XBI rose 3.1% and the broader market also gained. In this Talk Tickers episode the hosts ask the question analysts kept pressing on the call: how much of that $31 million is lasting patient demand and how much is specialty pharmacy stocking. CEO Matt Gline said there were hundreds of patients on paid drug at September 30 and many hundreds now, with many hundreds of prescribers, said a meaningful amount of undispensed drug sat at pharmacies at quarter end and has since been dispensed, and guided to a modest headwind from those dynamics in the December quarter. Jefferies analyst Dennis Ding called it tough to square the math, and the hosts walk through how revenue is booked when pharmacies buy the drug and why early payer access, which management described as straightforward so far, may tighten as plans put formal policies in place.

The middle of the episode turns to the pipeline. Immunovant's IMVT-1402, an anti-FcRn antibody, met its primary endpoint in Period 2 of a randomized withdrawal study in difficult-to-treat rheumatoid arthritis: 92.5% of patients kept on 600 mg maintained an ACR20 response at week 28 versus 75.6% on placebo, and ACR50 was 80.0% versus 56.1%, while the 300 mg dose did not separate from placebo. Gline says that supports the idea that depth of IgG suppression matters, and puts the refractory U.S. population at about 85,000 patients. FDA discussions on the registrational path are still ongoing, with an update expected later this year or early next year, and Gline thinks the Phase 3 is more likely to be a straightforward randomized controlled trial than another randomized withdrawal design. Roivant also said it is unlikely to take IMVT-1402 beyond its ongoing, fully enrolled Phase 2 in Sjögren's disease, which it will run to completion, citing competitor data including argenx's futility result. The hosts then cover brepocitinib in non-infectious uveitis, where the Phase 3 CLARITY trials showed median time to treatment failure of more than 48 weeks versus about 12 weeks on placebo and 62% versus 20% steroid-free quiescence at week 48, with a supplemental NDA planned for the first half of calendar 2027, and Pulmovant's mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD), where the Phase 2 PHocus study showed a 56.3% placebo-adjusted reduction in pulmonary vascular resistance and a 35.2 meter six-minute walk improvement at week 16, with the Phase 3 PHrontier study now enrolling.

Finally, the balance sheet. The $4.2 billion includes the $950 million initial payment Genevant and Arbutus received from Moderna in July 2026 under a global patent settlement, and a further $1.3 billion contingent payment depends on the outcome of Moderna's Section 1498 appeal, which is still unresolved. Roivant repurchased about 9.4 million shares for roughly $280 million over the six months to September 30, including 2.1 million shares for about $72.5 million in the quarter, while R&D spending fell to $145.7 million and SG&A rose to $154.1 million with the launch. The episode closes with the show's speculative, theoretical 'not financial advice' options idea built around two catalysts, the December quarter LISRAYA print and the Moderna appeal, plus a thought experiment on whether a cash-rich Roivant could turn acquirer. Upcoming catalysts include Roivant's Investor Day in New York on December 9, 2026, IMVT-1402 topline data in Graves' disease and myasthenia gravis in 2027, and whether LISRAYA demand holds once pharmacy stocking normalizes.

Talk Tickers - AI-powered earnings call analysis for retail investors.

AI Disclaimer: This podcast was generated with AI assistance using the actual earnings call transcript as source material.

Financial Disclaimer: This content is for informational and entertainment purposes only and should not be considered financial advice. Always do your own research or consult a financial advisor before making investment decisions.

#finance #investing #earnings

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
Roivant (ROIV) Q2 2026 Earnings: Revenue $35.1M, LISRAYA $31.0M

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]